243 related articles for article (PubMed ID: 11465303)
1. Cost effectiveness of desirudin compared with a low molecular weight heparin in the prevention of deep vein thrombosis after total hip replacement surgery.
Levin LA; Bergqvist D
Pharmacoeconomics; 2001; 19(5 Pt 2):589-97. PubMed ID: 11465303
[TBL] [Abstract][Full Text] [Related]
2. Economic evaluation of desirudin vs heparin in deep vein thrombosis prevention after hip replacement surgery.
Levin LA; Horst M; Bergqvist D
Pharmacoeconomics; 1998 Jan; 13(1 Pt 2):111-8. PubMed ID: 10176145
[TBL] [Abstract][Full Text] [Related]
3. New therapeutic options in deep vein thrombosis prophylaxis.
Eriksson BI
Semin Hematol; 2000 Jul; 37(3 Suppl 5):7-9. PubMed ID: 11055889
[TBL] [Abstract][Full Text] [Related]
4. A comparison of recombinant hirudin with a low-molecular-weight heparin to prevent thromboembolic complications after total hip replacement.
Eriksson BI; Wille-Jørgensen P; Kälebo P; Mouret P; Rosencher N; Bösch P; Baur M; Ekman S; Bach D; Lindbratt S; Close P
N Engl J Med; 1997 Nov; 337(19):1329-35. PubMed ID: 9358126
[TBL] [Abstract][Full Text] [Related]
5. Results of an economic model to assess the cost-effectiveness of enoxaparin, a low-molecular-weight heparin, versus warfarin for the prophylaxis of deep vein thrombosis and associated long-term complications in total hip replacement surgery in the United States.
Botteman MF; Caprini J; Stephens JM; Nadipelli V; Bell CF; Pashos CL; Cohen AT
Clin Ther; 2002 Nov; 24(11):1960-86; discussion 1938. PubMed ID: 12501885
[TBL] [Abstract][Full Text] [Related]
6. Prolonged enoxaparin therapy to prevent venous thromboembolism after primary hip or knee replacement. A cost-utility analysis.
Haentjens P; De Groote K; Annemans L
Arch Orthop Trauma Surg; 2004 Oct; 124(8):507-17. PubMed ID: 15365714
[TBL] [Abstract][Full Text] [Related]
7. Cost implications of low molecular weight heparins as prophylaxis following total hip and knee replacement.
Bell GK; Goldhaber SZ
Vasc Med; 2001; 6(1):23-9. PubMed ID: 11358156
[TBL] [Abstract][Full Text] [Related]
8. A probabilistic cost-effectiveness analysis of enoxaparin versus unfractionated heparin for the prophylaxis of deep-vein thrombosis following major trauma.
Lynd LD; Goeree R; Crowther MA; O'Brien BJ
Can J Clin Pharmacol; 2007; 14(2):e215-26. PubMed ID: 17652767
[TBL] [Abstract][Full Text] [Related]
9. Desirudin: a review of its use in the management of thrombotic disorders.
Matheson AJ; Goa KL
Drugs; 2000 Sep; 60(3):679-700. PubMed ID: 11030473
[TBL] [Abstract][Full Text] [Related]
10. The cost-effectiveness of oral direct factor Xa inhibitors compared with low-molecular-weight heparin for the prevention of venous thromboembolism prophylaxis in total hip or knee replacement surgery.
Mahmoudi M; Sobieraj DM
Pharmacotherapy; 2013 Dec; 33(12):1333-40. PubMed ID: 23625693
[TBL] [Abstract][Full Text] [Related]
11. Prevention of thromboembolism with use of recombinant hirudin. Results of a double-blind, multicenter trial comparing the efficacy of desirudin (Revasc) with that of unfractionated heparin in patients having a total hip replacement.
Eriksson BI; Ekman S; Lindbratt S; Baur M; Bach D; Torholm C; Kälebo P; Close P
J Bone Joint Surg Am; 1997 Mar; 79(3):326-33. PubMed ID: 9070519
[TBL] [Abstract][Full Text] [Related]
12. Pharmacoeconomic analysis of bemiparin and enoxaparin as prophylaxis for venous thromboembolism in total knee replacement surgery.
Honorato J; Gómez-Outes A; Navarro-Quilis A; Martínez-González J; Rocha E; Planès A
Pharmacoeconomics; 2004; 22(13):885-94. PubMed ID: 15329033
[TBL] [Abstract][Full Text] [Related]
13. Rivaroxaban for the prevention of venous thromboembolism: a single technology appraisal.
Stevenson M; Scope A; Holmes M; Rees A; Kaltenthaler E
Health Technol Assess; 2009 Oct; 13 Suppl 3():43-8. PubMed ID: 19846028
[TBL] [Abstract][Full Text] [Related]
14. Cost effectiveness of bemiparin sodium versus unfractionated heparin and oral anticoagulants in the acute and long-term treatment of deep vein thrombosis.
Gómez-Outes A; Rocha E; Martínez-González J; Kakkar VV
Pharmacoeconomics; 2006; 24(1):81-92. PubMed ID: 16445305
[TBL] [Abstract][Full Text] [Related]
15. Enoxaparin for thromboprophylaxis after major trauma: potential cost implications.
Shorr AF; Ramage AS
Crit Care Med; 2001 Sep; 29(9):1659-65. PubMed ID: 11546959
[TBL] [Abstract][Full Text] [Related]
16. New therapeutic options in DVT prophylaxis.
Wille-Jørgensen P
Orthopedics; 2000 Jun; 23(6 Suppl):s639-42. PubMed ID: 10875428
[TBL] [Abstract][Full Text] [Related]
17. Long-term cost-effectiveness of low molecular weight heparin versus unfractionated heparin for the prophylaxis of venous thromboembolism in elective hip replacement.
Marchetti M; Liberato NL; Ruperto N; Barosi G
Haematologica; 1999 Aug; 84(8):730-7. PubMed ID: 10458700
[TBL] [Abstract][Full Text] [Related]
18. Out of hospital antithrombotic prophylaxis after total hip replacement: low-molecular-weight heparin, warfarin, aspirin or nothing? A cost-effectiveness analysis.
Sarasin FP; Bounameaux H
Thromb Haemost; 2002 Apr; 87(4):586-92. PubMed ID: 12008939
[TBL] [Abstract][Full Text] [Related]
19. Desirudin: a review of the pharmacology and clinical application for the prevention of deep vein thrombosis.
Graetz TJ; Tellor BR; Smith JR; Avidan MS
Expert Rev Cardiovasc Ther; 2011 Sep; 9(9):1101-9. PubMed ID: 21932952
[TBL] [Abstract][Full Text] [Related]
20. Cost consequence analysis of fondaparinux versus enoxaparin in the prevention of venous thromboembolism after major orthopaedic surgery in Belgium.
Annemans L; Minjoulat-Rey MC; De Knock M; Vranckx K; Czarka M; Gabriel S; Haentjens P
Acta Clin Belg; 2004; 59(6):346-57. PubMed ID: 15819379
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
